Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376239 | 0.85 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL8658099 | 0.80 | PTGS2 (0.72) | PTGS2 | |
| SCHEMBL8974192 | 0.80 | PTGS2 (0.44) | ENPP2PTGS2 | |
| SCHEMBL17642663 | 0.79 | CA1 (0.46) | ENPP2CA1CA2MMP1MMP2 | |
| SCHEMBL7677302 | 0.77 | PTGS2 (0.62) | ENPP2CA2PTGS2 | |
| SCHEMBL896933 | 0.77 | RAPGEF4 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL17548700 | 0.77 | ENPP2 (0.62) | ENPP2PTGS2 | |
| SCHEMBL13662414 | 0.77 | CA1 (0.42) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL10300269 | 0.77 | PTGS2 (0.62) | ENPP2CA2PTGS2 | |
| SCHEMBL24899771 | 0.75 | F2 (0.44) | ENPP2CA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117088909-A | Method for producing aryltrimethylstannane compound | 上海致同建设工程科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-12325696-B2 | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-06-10 | — | — | US | disclosed |
| CN-119320379-A | Indazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-113874367-B | Indazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240239746-A1 | PREPARATION METHOD FOR PYRROLE AMIDE COMPOUND | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| CN-115246785-B | Process for preparing pyrrole amide compounds | 年衍药业(珠海)有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4332091-A1 | PREPARATION METHOD FOR PYRROLE AMIDE COMPOUND | Sunshine Lake Pharma Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| CN-117088909-A | Method for producing aryltrimethylstannane compound | 上海致同建设工程科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-101415716-A | Condensed imidazole derivatives as aldosterone synthase inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2009-04-22 | — | — | CN | disclosed |
| EP-1385508-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-05-21 | — | — | EP | disclosed |
| WO-2008041053-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| CN-1028521-C | Therapeutic agents | BOOTS CO PLC (GB) | 1995-05-24 | — | — | CN | disclosed |
| EP-0536151-B1 | ORTHOSUBSTITUTED BIPHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | BOOTS CO PLC (GB) | 1994-09-14 | — | — | EP | disclosed |
| US-5302720-A | Biphenyl-substituted guanidine derivatives useful as hypoglycaemic agents | THE BOOTS COMPANY (GB) | 1994-04-12 | — | — | US | disclosed |
| CN-1072173-A | Therapeutical agent | BOOTS CO PLC (GB) | 1993-05-19 | — | — | CN | disclosed |
| EP-0536151-A1 | ORTHOSUBSTITUTED BIPHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM. | BOOTS CO PLC (GB) | 1993-04-14 | — | — | EP | disclosed |
| WO-1992000273-A1 | ORTHOSUBSTITUTED BIPHENYL AMIDINE AND BIPHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | THE BOOTS COMPANY PLC (GB) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12325696-B2 | Indazole derivative, preparation method therefor, and pharmaceutical application thereof | CYP19A1, HSD17B11, CYP51A1 | ENPP2 3969/4885CA1 4362/4885CA2 4308/4885 |
| US-20240239746-A1 | PREPARATION METHOD FOR PYRROLE AMIDE COMPOUND | HPGDS, HRH4, FAAH | ENPP2 3404/4885CA1 3225/4885CA2 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.